Exenatide
Acquired Hypothalamic Obesity
University Hospital, Bordeauxprotein_peptidePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Acquired Hypothalamic Obesity cohort.
View all 14 →
Same molecule, other indications
Exenatide is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative · Phase 4
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →